Universal Health Realty Income Trust (UHT) Investment Analysis
Universal Health Realty Income Trust (UHT) operates as a specialized, healthcare-focused real estate investment trust (REIT) that acquires, owns, and manages a highly defensive portfolio of clinical and medical properties across the United States.[1, 2] Founded in 1986 and structured as a Maryland trust, the entity's core investment strategy centers on securing stable, long-term, inflation-protected cash flows by leasing mission-critical healthcare infrastructure to institutional operators.[1, 3] As of late February 2026, UHT’s diversified portfolio comprised seventy-seven real estate investments or commitments distributed across twenty-one states.[1, 4] The underlying assets are structurally aligned with modern clinical delivery models, consisting of six hospital facilities (representing both acute care and behavioral health care specialties), sixty-one medical office buildings (MOBs), four free-standing emergency departments (FEDs), four preschool childcare centers, one specialty medical facility, and strategic packages of vacant land earmarked for clinical development.[1]
UHT Portfolio Composition & Revenue Yield (FY2025):
+--------------------------------------+-------------------------+-------------------------+
| Property Category | Number of Assets | Asset Value Contribution|
+--------------------------------------+-------------------------+-------------------------+
| Medical Office Buildings / Clinics | 61 Assets | 71% of Portfolio |
| Acute Care Hospitals | 4 Facilities | 17% of Portfolio |
| Behavioral Health Care Hospitals | 2 Facilities | 7% of Portfolio |
| Ambulatory Care / FEDs | 4 Assets | 3% of Portfolio |
| Specialty Facilities | 1 Asset | 1% of Portfolio |
| Childcare Centers | 4 Centers | 1% of Portfolio |
+--------------------------------------+-------------------------+-------------------------+
Source: Universal Health Realty Income Trust Form 10-K [1, 4]
The trust generates its consolidated revenues through two primary commercial mechanisms: contractually recurring rental payments under triple-net lease agreements and interest income derived from long-term financing lease structures.[3, 5] UHT's geographic footprint is strictly domestic, with assets strategically positioned near major metropolitan health networks to capture localized demand.[3, 4] The trust’s customer base is heavily concentrated, with its most significant commercial tenant and strategic partner being Universal Health Services, Inc. (UHS), one of the nation's largest and most financially robust hospital management companies.[1, 6] Subsidiaries of UHS lease all six of the trust's hospital facilities and occupy nineteen additional properties, collectively generating approximately 40% to 41% of UHT's consolidated revenues.[1, 7] Operationally, UHT’s management is also programmatic; a wholly owned subsidiary of UHS (UHS of Delaware, Inc.) serves as the trust’s Advisor under a renewable agreement, earning an annual fee of 0.70% of UHT's average invested real estate assets.[1]
Healthcare operators select UHT over capital alternatives because of its deep understanding of clinical operations, its willingness to provide flexible, long-term capital through sale-leaseback or build-to-suit structures, and its alignment with the broader UHS healthcare ecosystem.[3, 8] Unlike generalized commercial landlords, UHT's specialization allows it to underwrite complex medical credits and design leases with terms that accommodate long-term clinical development.[3, 9] This operational alignment provides UHT with high tenant retention and a predictable income profile, supporting its history of thirty-nine consecutive years of uninterrupted dividend growth.[4, 8]
UHT does not provide clinical services, employ medical personnel, or bill public and private insurers.[3] Instead, the trust operates as a specialized landlord and capital provider, selling physical clinical capacity and structured real estate financing solutions.[3, 9] The trust’s primary commercial products consist of:
* Triple-Net Triple-Option Leases: Utilized primarily for hospital assets, these structures obligate the tenant to pay all property-level operating expenses—including real estate taxes, property insurance, utilities, and routine maintenance—insulating UHT's net operating income from operational inflation.[3, 10] These leases typically carry initial durations of ten to twenty years and contain fixed or inflation-indexed rent escalators alongside multiple five-year renewal options.[1]
* Multi-Tenant Medical Office Leases: Designed for MOBs, these agreements feature shorter durations (typically three to seven years) and provide UHT with internal leasing upside.[3] While more operationally intensive than single-tenant hospital leases, MOBs diversify tenant credit risk across various outpatient specialties, diagnostic providers, and private physician groups.[3]
* Financing Receivables: Structured transactions under which UHT provides real estate-backed financing to health systems.[3, 9] As of late 2025, UHT held $82.1 million in financing receivables linked to a transaction with UHS, yielding $5.4 million in annualized interest income.[11]
UHT possess a narrow, highly defensive competitive moat built upon high switching costs, localized network effects, and a structural advisory alignment with UHS [3, 8]:
* High Switching Costs: Moving a clinical facility is highly complex due to extensive regulatory oversight, certificate-of-need (CON) barriers, and specialized equipment installation costs.[8, 9] Rebuilding a specialized medical facility requires millions in capital and years of regulatory delays.[3, 9] Consequently, tenant retention at UHT’s single-tenant properties is close to 100%, providing highly predictable cash flows.[1, 3]
* Advisory Information Advantage: The advisory agreement with UHS of Delaware grants UHT access to market intelligence regarding clinical volumes, local market market-share dynamics, and regulatory compliance trends.[1, 8] This relationship allows UHT to underwrite operator credits with greater precision than generic real estate investors.[3, 8]
* Ecosystem Integration: Many of UHT's medical office assets are physically integrated into existing hospital campuses owned by UHS, creating a structural lock-in.[4, 12] Physician groups leasing space in these MOBs rely on direct physical access to the adjacent acute care hospitals for diagnostic referrals and surgical access, reinforcing occupancy stability.[3, 4]
The expansion of UHT's market opportunity is driven by secular macroeconomic tailwinds.[2, 13] The aging of the U.S. population is a predictable demographic driver, with the over-65 cohort projected to grow significantly, consuming clinical clinical services at three to four times the rate of younger demographics. Concurrently, technological and regulatory changes are shifting clinical delivery away from high-cost inpatient hospital beds toward lower-cost, highly convenient outpatient environments.[2, 8] This structural shift expands the target market for medical office buildings, ambulatory surgery clinics, and free-standing emergency departments—the exact asset classes that represent more than 74% of UHT’s current portfolio.[4, 8]
The healthcare real estate sector is highly competitive and bifurcated.[3, 9] UHT competes against diversified national healthcare REITs, such as Welltower, Inc. (WELL) and Ventas, Inc. (VTR), which possess lower costs of capital and greater scale.[9, 13] UHT also competes against a peer group of mid- and small-cap healthcare specialists, including Community Healthcare Trust (CHCT), LTC Properties (LTC), and American Healthcare REIT (AHR).[14, 15]
UHT holds its ground in this competitive landscape by avoiding volatile senior housing operating portfolios (SHOP) and skilled nursing assets, focusing instead on stable medical office and acute care structures.[3, 8] While UHT's small scale prevents it from pursuing large national portfolios, its strategic partnership with UHS allows it to secure high-barrier, campus-adjacent developments.[8, 12] The trust is currently maintaining its market position rather than aggressively gaining share, prioritizing capital preservation and dividend stability over aggressive acquisition-driven growth.[3, 8]
UHT reported its quarterly financial results for the period ended March 31, 2026, on April 27, 2026.[12, 16, 17] The results demonstrate stable, defensive operational execution.[7]
Universal Health Realty Income Trust - Key Q1 Financial Performance (USD in thousands):
+-------------------------------------------------+-------------+-------------+------------+
| Metric | Q1 2026 | Q1 2025 | YoY Change |
+-------------------------------------------------+-------------+-------------+------------+
| Lease Revenue - UHS Facilities | $8,383 | $8,327 | +0.67% |
| Lease Revenue - Non-Related Parties | $14,202 | $14,326 | -0.87% |
| Other Revenue - UHS Facilities | $236 | $229 | +3.06% |
| Other Revenue - Non-Related Parties | $366 | $314 | +16.56% |
| Interest Income on Financing Leases - UHS | $1,342 | $1,352 | -0.74% |
| Total Revenues | $24,529 | $24,548 | -0.08% |
| Depreciation & Amortization | $6,954 | $6,845 | +1.59% |
| Advisory Fees to UHS | $1,403 | $1,364 | +2.86% |
| Other Operating Expenses | $7,215 | $7,305 | -1.23% |
| Net Income | $5,019 | $4,777 | +5.07% |
| Diluted Earnings Per Share | $0.36 | $0.34 | +5.88% |
| Funds From Operations (FFO) | $12,266 | $11,930 | +2.82% |
| Funds From Operations (FFO) Per Diluted Share | $0.88 | $0.86 | +2.33% |
+-------------------------------------------------+-------------+-------------+------------+
Source: Universal Health Realty Income Trust Q1 2026 Form 10-Q [5, 7]
Consolidated revenues remained flat, decreasing by a marginal 0.08% to $24.53 million.[5] Net income increased by 5.07% to $5.02 million, driven primarily by lower interest expenses resulting from a decrease in the trust's average effective borrowing rate, which was secured through active interest rate swap agreements.[5, 18] GAAP diluted earnings per share rose to $0.36 from $0.34 in the prior-year quarter.[5, 7] Funds From Operations (FFO), the primary metric of recurring real estate cash flow, grew by 2.82% to $12.27 million, or $0.88 per diluted share, up from $11.93 million ($0.86 per share) in Q1 2025.[5, 18]
Due to its small-cap structure, UHT does not have active sell-side consensus coverage, and formal consensus analyst estimates for quarterly revenue and earnings per share were not publicly compiled for Q1 2026.[10] UHT maintains a corporate policy of not issuing short-term numerical earnings or FFO guidance, preferring to let its long-term lease structures dictate market expectations.[3] However, competitor and primary tenant UHS did provide formal full-year 2026 guidance, forecasting net revenues of $18.417 billion to $18.789 billion and diluted EPS of $22.64 to $24.52.[19]
Management's commentary focused on UHT's capital structure and hedging strategies.[5, 18] The trust's average effective borrowing rate benefited from its interest rate swap portfolio, which hedged a significant portion of its floating-rate debt.[5, 18] UHT's active swaps as of March 31, 2026, include:
* An $85 million swap at a fixed rate of 3.2725% maturing on September 30, 2028.[5]
* A $25 million swap at a fixed rate of 3.9495% maturing on December 1, 2027.[5]
* A $55 million swap at a rate of 0.565% (modified to Term SOFR) maturing on March 25, 2027.[5]
On April 24, 2026, UHT successfully amended its credit agreement, increasing its borrowing capacity to $475 million from $425 million, which provides approximately $115 million in available capacity to fund its capital pipeline.[8, 12] The primary deployment of this liquidity is the Miller Medical Plaza development in Palm Beach Gardens, Florida.[8, 12] This $34 million, 80,000-square-foot MOB is located adjacent to a newly constructed UHS acute care hospital.[4, 12] The project is supported by a 10-year master flex lease with UHS covering 75% of the rentable square footage, which commenced in early 2026, ensuring high immediate occupancy upon its expected completion in late Q4 2026.[4, 8, 12]
Following the Q1 2026 release, UHT’s stock price reacted positively, gaining $2.03 per share, reflecting investor optimism regarding steady FFO growth and stable interest costs.[10] Sell-side ratings remained unchanged, with the consensus target price holding steady at $42.00, implying the stock is fully valued near its current market level.[15, 20]
UHT's current market valuation is shaped by its modest growth profile and defensive capital structure.[8, 14] As of July 5, 2026, UHT trades at $45.82.[15]
UHT Valuation Profile & Capital Structure (LTM):
+------------------------------------------+-------------------------+
| Metric | Current Valuation Value |
+------------------------------------------+-------------------------+
| Share Price (July 5, 2026) | $45.82 [15] |
| Shares Outstanding | 13.88 million [21] |
| Market Capitalization | $635.78 million [21] |
| Enterprise Value (EV) | $1.02 billion [21] |
| Trailing 12-Month (TTM) Revenue | $100.97 million [2] |
| FFO Per Share (Forward Run-Rate) | $3.46 [21] |
| Price-to-FFO (Forward Run-Rate) | 13.24x [21] |
| Dividend Yield (Annualized $3.00 rate) | 6.55% [21] |
| Debt-to-Equity Ratio | 255.6% [22] |
| Interest Coverage Ratio | 2.0x [22] |
+------------------------------------------+-------------------------+
Source: Consolidated Exchange Data and Balance Sheet Disclosures [2, 21, 22]
To understand UHT's core valuation, investors should evaluate its five-year historical revenue growth.[15, 23] From FY2020 (revenues of ~$78 million) to FY2025 (revenues of $99.2 million), UHT's revenue expanded at a compound annual growth rate (CAGR) of 4.92%.[11, 13, 15] The compounding revenue growth can be modeled as:
$R_t = R_0 \times (1 + g)^t$
Where $R_t$ is Year 5 revenue, $R_0$ is base year revenue, $g$ is the revenue growth rate ($4.92\%$), and $t$ is time in years ($t=5$).[11, 13, 15] This mid-single-digit growth reflects the stable, index-linked rent escalators embedded in UHT's triple-net lease agreements, paired with selective portfolio acquisitions.[1, 3]
Because high non-cash depreciation charges lower GAAP net income, traditional price-to-earnings (P/E) multiples are less useful for REIT valuations.[13] Investors focus instead on the Price-to-FFO multiple, which is calculated as:
$\text{FFO per share} = \frac{\text{Net Income} + \text{Depreciation adjustments}}{\text{Diluted share count}}$ [7, 11]
At 13.24x FFO, UHT trades at a discount to its historical 10-year average multiple of ~17x, reflecting market caution regarding elevated interest rates and the trust's high tenant concentration with UHS.[13, 21]
UHT's key execution risk lies in the management of its development pipeline.[4, 8] Constructing specialized clinical properties requires significant capital and strict adherence to timelines.[3, 9] The trust is currently funding the $34 million Miller Medical Plaza project; any labor bottlenecks, zoning disputes, or raw material cost inflation could reduce the development's yield and delay occupancy.[4, 12]
Additionally, UHT faces frictional vacancy in its non-UHS medical office portfolio.[11, 24] For example, a medical office building in Amarillo, Texas, was completely vacated in Q4 2025 following lease expirations, removing $545,000 from annualized rental revenues.[11] From a competitive standpoint, UHT's small size limits its capacity to pursue large healthcare portfolios, leaving it vulnerable to being outbid by larger peers with lower capital costs.[9, 13]
UHT’s primary operational risk is its significant customer concentration.[1, 3] Properties leased to UHS subsidiaries generate approximately 41% of consolidated revenues.[7] Consequently, any financial or regulatory headwind facing UHS directly impacts UHT.[1, 3] In early 2026, UHS experienced a decline in same-facility adjusted admissions for Affordable Care Act (ACA) exchange patients, leading to an estimated $75 million pre-tax headwind for its hospital operations.[25] If UHS hospital operations face structural labor shortages, rising nurse staffing agency costs, or insurance reimbursement audits, its ability to support its triple-net obligations to UHT could weaken.[1, 3, 25]
Furthermore, UHT's tenants rely heavily on federal and state healthcare reimbursement programs, specifically Medicare and Medicaid.[1, 26] Structural changes or funding cuts to state Medicaid programs would directly pressure operator cash flows and rent coverage ratios.[26]
UHT's capital allocation strategy relies heavily on floating-rate credit borrowings, exposing it to interest rate volatility.[14, 22] As of March 31, 2026, UHT carried $359.5 million in outstanding credit facility debt.[7, 8] Although $165 million of this exposure is hedged through interest rate swaps, the remaining unhedged debt is sensitive to rate fluctuations.[5, 14] With a net interest coverage ratio of approximately 2.0x, any prolonged increase in benchmark interest rates would increase interest expenses, narrowing the cash flow cushion available to support its annualized dividend.[14, 22]
UHT Risk Analysis Matrix:
+------------------------------------+--------------------------------------+----------------------------------------+
| Operational Risk Scenario | Early Warning Indicator | Long-Term Structural Damage |
+------------------------------------+--------------------------------------+----------------------------------------+
| Debt service costs consume FFO | Net interest coverage drops below | Variable borrowing rates exceed 7%, |
| margin, threatening dividend. | 1.8x; swap spreads compress. | forcing a structural dividend cut. |
+------------------------------------+--------------------------------------+----------------------------------------+
| Frictional vacancy rises, leading | MOB portfolio occupancy falls | Structural adoption of telehealth |
| to asset write-downs. | below 75% (2025: ~78% [24]). | reduces physical clinical demand. |
+------------------------------------+--------------------------------------+----------------------------------------+
| Major lease defaults at UHS | UHS EBITDAR hospital lease coverage | UHS experiences financial restructuring|
| hospital facilities. | falls below 2.0x (2025: 8.6x [1]).| and rejects master lease obligations. |
+------------------------------------+--------------------------------------+----------------------------------------+
Source: Analyst risk synthesis of balance sheet and portfolio operational metrics [1, 3, 14, 22, 24]
To evaluate the long-term total return profile of UHT over a five-year holding period (ending in mid-2031), three distinct operational scenarios are modeled. These models utilize UHT’s actual current capital metrics as their analytical starting point: a current share price of $45.82 [15], 13.88 million diluted shares outstanding [15, 21], trailing revenue of $99.2 million [14, 22], FFO per diluted share of $3.44 [11], and an annualized dividend rate of $3.00.[2, 21]
Additionally, all three scenarios integrate the significant capital contribution of UHT's long-term financing lease receivables from UHS, which stood at $82.1 million as of late 2025 and generate $5.4 million in annual interest income, supporting the trust's dividend-paying capacity.[11]
The Base Case assumes UHT maintains its historical, low-single-digit organic growth trajectory.[13] The Miller Medical Plaza and other modest outpatient developments are successfully delivered, offset by standard frictional vacancy in the older MOB portfolio.[4, 8, 24]
* Operating Assumptions: Revenue grows at a 2.5% CAGR over 5 years, reaching $112.21 million by Year 5.[13] The FFO margin remains stable at 48.0% as interest rate swaps are rolled over at current market rates.[7, 14] The trust issues minimal equity (1.0% annual dilution) to maintain its debt covenants, resulting in a Year 5 share count of 14.59 million.[13]
* Earnings & Valuation: Implied Year 5 FFO rises to $53.86 million, translating into $3.70 FFO per share. Applying a historical fair value multiple of 13.5x FFO reflects a stable macro environment.[13]
* Implied Share Price (USD) & Total Return: The projected share price is $49.95. Over 5 years, the trust pays out $15.50 in cumulative dividends (assuming 1.5% annual dividend growth). Implied total return is 42.8%, representing an annualized return of 7.4%.
The High Case assumes a favorable macroeconomic shift characterized by aggressive Federal Reserve interest rate cuts, which lowers variable borrowing costs and drives capital into defensive, high-yield REITs.[14, 27, 28]
* Operating Assumptions: Revenue grows at a 4.5% CAGR to $123.62 million, driven by positive leasing spreads in the MOB portfolio and successful follow-on development projects on UHS campuses.[4, 8] Lower interest rates expand the FFO margin to 51.0%.[7] Share count is restricted to 14.30 million due to stronger cash retention.
* Earnings & Valuation: Implied Year 5 FFO reaches $63.05 million, or $4.41 per share. The exit P/FFO multiple expands to 16.0x as yield-seeking capital drives valuation multiple expansion.[13, 29]
* Implied Share Price (USD) & Total Return: The projected share price is $70.56. Cumulative dividends paid equal $16.50. Implied total return is 90.0%, representing an annualized return of 13.7%.
The Low Case models a persistent high-interest-rate environment, combined with localized recessions and tenant operational distress.[14, 25, 26]
* Operating Assumptions: Revenue growth stagnates at a 0.5% CAGR, reaching $101.70 million, as vacancy rates in the third-party MOB portfolio rise to 25%.[24] High variable borrowing rates on the unhedged credit facility compress the FFO margin to 44.0%.[14, 22] The trust is forced to issue dilutive equity to preserve capital, expanding the share count to 15.00 million.
* Earnings & Valuation: Implied Year 5 FFO falls to $44.75 million, or $2.98 per share. The exit P/FFO multiple de-rates to 10.0x due to fears over dividend sustainability.[13]
* Implied Share Price (USD) & Total Return: The projected share price falls to $29.80. Dividends are frozen or slightly reduced to preserve liquidity, yielding $14.50 in cumulative payments. Implied total return is -3.3%, representing an annualized return of -0.7%.
Projected Share Price Trajectories over 5 Years (all figures in USD):
+--------------------+------------+------------+------------+------------+------------+------------+
| Scenario | Year 0 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
+--------------------+------------+------------+------------+------------+------------+------------+
| High Case (25%) | $45.82 | $49.88 | $54.30 | $59.12 | $64.55 | $70.56 |
| Base Case (50%) | $45.82 | $46.61 | $47.42 | $48.25 | $49.09 | $49.95 |
| Low Case (25%) | $45.82 | $41.90 | $38.31 | $35.03 | $32.22 | $29.80 |
+--------------------+------------+------------+------------+------------+------------+------------+
Source: Valuation projection models based on exit FFO assumptions [13, 15, 21]
UHT's weighted-average 5-year target price can be calculated as:
$P_{\text{Weighted}} = \sum_{i=1}^{n} (w_i \times P_i)$ [13, 15, 21]
$P_{\text{Weighted}} = (0.25 \times 70.56) + (0.50 \times 49.95) + (0.25 \times 29.80) = 50.07 \text{ USD}$ [13, 15, 21]
This probability-weighted target price represents a potential 5-year capital appreciation of 9.27% above the current share price of $45.82, plus cumulative dividend distributions.[15]
Universal Health Realty Income Trust - 5-Year Valuation Scenario Matrix:
+----------+--------------------+----------------------------+-------------------------+---------------------+----------------------------+---------------------+-------------------+-------------+
| Scenario | Year 5 Revenue | Year 5 FFO Margin | Exit P/FFO Multiple | Current Share Price | Implied Future Share Price | 5-Year Total Return | Annualized Return | Probability |
+----------+--------------------+----------------------------+-------------------------+---------------------+----------------------------+---------------------+-------------------+-------------+
| High | $123.62 million | 51.00% | 16.0x | $45.82 | $70.56 | 90.0% | 13.7% | 25% |
| Base | $112.21 million | 48.00% | 13.5x | $45.82 | $49.95 | 42.8% | 7.4% | 50% |
| Low | $101.70 million | 44.00% | 10.0x | $45.82 | $29.80 | -3.3% | -0.7% | 25% |
+----------+--------------------+----------------------------+-------------------------+---------------------+----------------------------+---------------------+-------------------+-------------+
Source: Financial modeling of FFO generation and capital allocation strategies [13, 15, 21]
STABLE PROXY BOND
To evaluate the qualitative factors driving UHT's performance, the trust is rated across ten categories on a scale of 1 to 10.
UHT's management alignment features strong, though complex, insider relationships.[1, 30] Chairman and CEO Alan B. Miller owns 224,104 shares directly (1.62% of outstanding shares), and the broader insider group controls approximately 2.61% of UHT.[30, 31] In addition, UHS itself holds a 5.68% stake in the trust.[31] Under the Amended and Restated 2007 Restricted Stock Plan, Miller received a grant of 6,247 restricted shares as equity compensation on June 11, 2026.[32] On October 30, 2025, Miller executed an open-market purchase of 12,247 shares at $37.02.[21] While these transactions align management with shareholders, the advisory structure paid to UHS of Delaware (totaling $5.6 million in 2025) presents potential governance conflicts.[30, 31] Management essentially operates on both sides of transaction tables, serving as both landlord and tenant.[1, 3]
The credit profile of UHT's single-tenant properties is exceptionally strong, backed by UHS corporate parent guarantees.[33] This stable core is balanced by the weaker credit profile and higher vacancy rates in the third-party MOB portfolio, where estimated occupancy fell to approximately 78% in late 2025.[24]
The trust occupies a niche space within the healthcare real estate market.[3] It is too small to compete with dominant diversified operators, which limits its ability to secure scale economies and proprietary national portfolios.[9, 13] However, its programmatic integration with UHS ensures it maintains a defensible position within its core markets.[1, 8]
UHT's organic expansion is structurally constrained by its capital allocation choices.[8, 13] Retaining a dividend payout ratio of ~85% to 91% leaves minimal cash to reinvest back into the business.[2, 8, 14] Consequently, UHT must rely on external capital raises or debt expansion to fund acquisitions, capping long-term FFO growth at a low-single-digit rate.[8, 13]
The trust displays solid short-term liquidity, with a current ratio of over 7.8x and comfortable headroom on its core credit covenants.[5, 15] However, UHT carries a highly leveraged balance sheet, with a debt-to-equity ratio of 255.6%.[22] Its trailing interest coverage ratio is thin at approximately 2.0x, making it sensitive to unhedged variable borrowing rates.[14, 22]
The long-term durability of healthcare real estate is highly secure.[2, 13] Demographic tailwinds are highly predictable, and the physical real estate assets are central to local healthcare delivery.[3, 8] UHT's asset mix avoids the highly volatile senior housing sector, focusing instead on more stable clinical outpatient facilities.[8]
Management has executed an exceptional, thirty-nine-year track record of consecutive dividend increases, showing a strong commitment to returning capital to shareholders.[4, 8] However, this high payout ratio limits internal compounding.[13] Additionally, the decision to engage in high-leverage development structures during high-interest periods raises capital efficiency concerns.[8, 14]
Wall Street analysts maintain a neutral outlook on UHT.[14, 15, 20] The consensus rating is a unanimous "Hold" with an average price target of $42.00.[15, 20] This target sits slightly below the current market price of $45.82, indicating that the professional investment community views the stock as fully valued at current levels.[15, 20]
The trust maintains healthy operating margins of 37.8% and a high gross margin of 94.4%, reflecting the efficient nature of the triple-net leasing model.[2, 21] However, net income margins are subject to volatility from non-cash depreciation and fluctuating interest charges.[13, 14]
UHT has successfully navigated multiple economic cycles since its founding in 1986, protecting its dividend-paying capacity through deep recessions and pandemics.[8, 15] However, GAAP earnings per share have declined at an annualized rate of 30.5% over the past five years, showing that underlying profitability has struggled to expand in recent years.[14]
DEFENSIVE INCOME VEHICLE
Universal Health Realty Income Trust’s investment profile is that of a stable, income-focused asset.[3, 8] The trust's core investment thesis rests on its defensive real estate portfolio and structural partnership with UHS, balanced by clear growth constraints:
* The Power of the UHS Relationship: Underpinned by UHS corporate parent guarantees, the trust’s acute-care and behavioral assets provide highly stable, inflation-indexed cash flows.[1, 33] This programmatic alignment provides UHT with access to stable, low-risk development pipelines like the Miller Medical Plaza project.[8, 12]
* Irreversible Demographic Tailwinds: The aging U.S. population and the systemic migration of clinical care away from high-cost inpatient beds toward outpatient clinics and medical offices support long-term demand for UHT's medical office portfolio.[2, 8]
* Structural Interest Rate Sensitivity: Carrying a debt-to-equity ratio of over 255% and an interest coverage ratio of approximately 2.0x, the trust's cost of debt remains high.[14, 22] Although active interest rate swaps hedge a significant portion of its variable debt, high benchmark rates continue to pressure the trust's net FFO margins.[5, 14]
* Growth and Valuation Balance: With a dividend payout ratio of 85% to 91% of FFO, UHT returns nearly all of its cash flow to shareholders, leaving minimal capital for reinvestment.[2, 8, 14] Consequently, UHT trades more like a proxy bond than a growth equity, with its current valuation of $45.82 and FFO multiple of 13.24x fairly reflecting this defensive, low-growth operational profile.[8, 14, 21]
UHT’s long-duration triple-net lease agreements, coupled with active hedging via interest rate swaps, should continue to insulate the trust from near-term operational volatility, protecting its dividend-paying capacity.[3, 5]
STABILITY OVER GROWTH
As of July 5, 2026, UHT's share price of $45.82 is trading 13.11% above its 200-day simple moving average (SMA) of $40.51 and 11.91% above its 50-day SMA of $40.94, showing intermediate-term bullish momentum.[21] The stock is trading near the top of its 52-week range of $35.26 to $46.30.[21] In the short term, UHT is likely to consolidate near its immediate resistance at $46.30, with support established at $41.08 and $37.16 as the market digests the trust's Q1 interest expense savings and steady FFO growth.[21, 28]
MOMENTUM FACES RESISTANCE
View Universal Health Realty Income Trust (UHT) stock page
Loading the interactive version of this report…